New tools to combat kidney fibrosis
Vanderbilt University Medical Center Research News Oct 21, 2017
Interstitial fibrosis contributes to chronic kidney disease, which is increasing in prevalence in the United States.
Raymond Harris, MD, and colleagues have previously implicated the epidermal growth factor receptor (EGFR) in the pathogenesis of diabetic nephropathy and kidney fibrosis, but the role of sustained EGFR activation in the renal tubule is unknown.
The investigators have now developed a mouse model of persistent EGFR activation in epithelial cells of the renal proximal tubule.
They demonstrated that the mice develop spontaneous, progressive tubulointerstitial fibrosis, characterized by epithelial cell dedifferentiation (loss of Âmature identity), increased numbers of myofibroblasts and immune cells, and increased matrix deposition. Genetic or pharmacologic inhibition of EGFR activity reduced fibrosis.
The study, reported in the October issue of The FASEB Journal, shows that sustained EGFR activation in the kidney causes kidney fibrosis. The mouse model provides a platform to identify novel targets and treatment strategies to combat fibrosis.
Go to Original
Raymond Harris, MD, and colleagues have previously implicated the epidermal growth factor receptor (EGFR) in the pathogenesis of diabetic nephropathy and kidney fibrosis, but the role of sustained EGFR activation in the renal tubule is unknown.
The investigators have now developed a mouse model of persistent EGFR activation in epithelial cells of the renal proximal tubule.
They demonstrated that the mice develop spontaneous, progressive tubulointerstitial fibrosis, characterized by epithelial cell dedifferentiation (loss of Âmature identity), increased numbers of myofibroblasts and immune cells, and increased matrix deposition. Genetic or pharmacologic inhibition of EGFR activity reduced fibrosis.
The study, reported in the October issue of The FASEB Journal, shows that sustained EGFR activation in the kidney causes kidney fibrosis. The mouse model provides a platform to identify novel targets and treatment strategies to combat fibrosis.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
